One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials

... company Alkermes exclusive rights to a library of compounds discovered by Wentland and his team. According to Alkermes, the library represents an opportunity for the company to ... nervous system disorders. Alkermes screened the library of compounds from Rensselaer and is responsible ...

InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer

... for cancer using InteRNA's proprietary library of miRNAs. Under the research collaboration, ... its unique lentiviral-based miRNA overexpression library in multi-parametric, high-throughput screening ... screens based on our proprietary miRNA library in the diverse research projects. This research ...

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

... PDGF inhibition. J Clin Invest. 2005 Oct;115(10):2811-21. 2. National library of Medicine Medical Encyclopedia. Pulmonary hypertension. ... Group. Posted 04/19/2007. 5. Internal Novartis data analysis 6. National library of Medicine Medical Encyclopedia. Idiopathic pulmonary fibrosis. ...

Bionovo's Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity

... that a study of the gene regulation in multiple cell lines by several of their estrogen receptor beta (ERb) candidates will be published in Public library of Science One. "In this study we show that plant-derived ERb compounds are as selective as synthetic compounds, but regulate different ...

In Rare Disorder, a Familiar Protein Disrupts Gene Function

... diagnostic tests for the disease, and also provide targets for eventual treatments. The study appeared May 26 in the online journal Public library of Science Biology (PloS Biology ). The study leader was Ian D. Krantz, M.D., a specialist in pediatric genetics at The Children's Hospital of ...

Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy

... is the root cause or major contributing factor for multiple medical conditions. Currently, Addrenex has three products in clinical trials and a library of over 400 compounds available for future development. For more information, go to www.addrenex.com . About SK Holdings (Released by SK ...

Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting

... diseases (pulmonary fibrosis), viral (HIV) and skin diseases (psoriasis and atopic dermatitis). Paloma owns the intellectual property relating to a library of novel, proprietary, small molecule drugs created through an integrated design platform incorporating proprietary, customized and industry standard ...

Doctors Urge Precaution to Shield Against Swine Flu

... been extensively studied in animals and humans, and is the subject of dozens of articles in peer-reviewed medical journals available via the National library of Medicine website, www.pubmed.gov . Clinical trials have shown that AHCC reliably helps to support NK cell activity in people with low NK cell ...

Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant

... for the diagnosis and treatment monitoring of Major Depressive Disorder (MDD). The company's products are derived from a proprietary Human Biomarker library and Hyper-Mapping(TM) technology. Ridge intends to develop a comprehensive neuropsychiatric disease diagnostic franchise. Ridge Diagnostics testing ...

Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication

... is the root cause or major contributing factor for multiple medical conditions. Currently, Addrenex has three products in clinical trials and a library of over 400 compounds available for future development. For more information go to www.addrenex.com . ...

Vantia Therapeutics' Pipeline Continues to Mature

... will be engaging with potential partners for these products. In addition, our preclinical progress emphasises the ability of Vantia's small molecule library to populate our pipeline and our expertise in this area.' Notes to Editors About Vantia Therapeutics: Vantia Therapeutics is a ...

DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology

... DSM employs the Trancerta(TM) Drug Delivery approach which is based on DSM's core strengths in polymers combined with its extensive in-house library of synthesis methods, formulation and processing techniques. DSM's current biomedical portfolio also includes ComfortCoat(TM) hydrophilic and ...

Risk of Stroke, Heart Disease in Women Lowered by Mediterranean Diet

... offers an undergraduate education for women, and renowned coeducational graduate programs in health sciences, education, liberal arts, social work, library and information science, and communications management, as well as the nation's first MBA program designed specifically for women. ...

Scientists Unmask Genetic Markers Associated With Psoriasis

... colleagues, links four psoriasis loci (IL12B, IL23A, IL23R and IL4/IL13) together in a common functional pathway. Implications The large library of genetic data increases the number of proteins and pathways that can be targeted by emerging therapies to fight psoriasis. Once the full ...

Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology

... cells into authentic induced pluripotent stem (iPS) cells has been published in PLoS Biology, the peer-reviewed scientific journal from the Public library of Science (PLoS)(1). This rapid and reliable new approach for generating pluripotent stem cells without using mammalian embryos uses the combination ...

Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415

... and enter human trials in a 2-year period, continuing the rapid pace of drug development at Addrenex. ADX415 was identified from an extensive library of alpha-2 adrenergic compounds that Addrenex licensed from the University of Nebraska Medical Center and that originated from Procter & ...

Cytopia Scientific Presentations on JAK2 Inhibitor Program

... biology program that has delivered multiple co-crystal structures of JAK2 bound with inhibitors. Cytopia has also developed an extensive chemical library of JAK2 inhibitors through an integrated computational and medicinal chemistry platform. Cytopia is developing a suite of JAK2 inhibitors for ...

Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera

... of insulin resistant diseases of Type II diabetes and metabolic syndrome (Syndrome X; pre-diabetic syndrome). Additionally, Napo has a plant library of approximately 2,300 medicinal plants from tropical regions, and Napo has entered two screening relationship associated with this collection. ...

Most Cancer Treatment Studies Aren't Published, Study Finds

... studies considered for publication be registered in a publicly accessible database like ClinicalTrials.gov . A subsequent search of the National library of Medicine's PubMed database showed that just 17.6 percent of the trials were eventually published in peer-reviewed medical journals. "We find that ...

Resveratrol Longevity Science Makes Dramatic U-Turn, But Resveratrol Supplements Remain Unchanged

... cell proliferation, and oxidative stress response, may play a stronger role than the Sirtuin1 gene in producing longevity. At the National library of Medicine online there are now 706 published journal reports on FOXO1, and 471 on Sirtuin1. In the gene array study published in the September 2008 ...

ProteoTech's Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimer's Disease

... and blood-brain-barrier penetration of Exebryl-1(R). Exebryl-1(R) is a novel small molecule drug developed at ProteoTech from its unique library of small molecule compounds designed to target specific amyloid diseases. Over six years of pre-clinical in vitro and in vivo testing led to the ...

Cytopia Appoints Study Chairman for JAK2 Clinical Trial

... program that has delivered multiple co-crystal structures of JAK2 complexed with inhibitors, and the subsequent development of an extensive chemical library of JAK2 inhibitors through an integrated computational and medicinal chemistry platform. Cytopia is developing a suite of JAK2 inhibitors for ...

BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting

... Thomas J. Simon, BioCryst's Senior Medical Advisor, stated, "Peramivir has now been studied in over 550 patients, allowing us to develop an extensive library of clinical knowledge about this potential therapy. The Shionogi Phase II study findings contribute important new information about the safety and ...

Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic

... or death. Joel Eisner, Ph.D., Associate Principal of Cato BioVentures, states, "We are fascinated with Abeome's ability to develop such a large library of monoclonal antibodies by use of their technology. They have pushed the bottleneck of therapeutic development to the screening step which ...

As Summer Heats Up, New Survey Reveals Need for Effective Sweat Treatments

... more about hyperhidrosis including key facts, statistics, and research studies, visit the International Hyperhidrosis Society's media resources and library online at: http://www.sweathelp.org/English/MP_Home.asp . About the Survey: This International Hyperhidrosis Society study was conducted ...

Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives

... Initiative to Feed Early-Stage Pipeline HGS has a rich heritage of scientific discovery that has produced a vast intellectual property estate and a library of thousands of therapeutic and diagnostic targets. Over the past couple of years, HGS has conducted a careful review and selected approximately 50 ...

Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma

... with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and drug discovery capabilities. Synta has a partnership with GlaxoSmithKline for the joint development and commercialization of its lead ...

Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease

... of our first clinical trial represents an important milestone for Cerenis, further validating our promising technology platform and our expanding library of investigational compounds to treat atherosclerosis. As we move forward with the clinical development program for CER-002, we will also continue ...

Napo Presents at ISPOR Meeting in Toronto

... for the treatment of insulin resistant diseases of Type II diabetes and metabolic syndrome (Syndrome X; pre-diabetic syndrome). Napo also has a plant library of approximately 2,300 medicinal plants from tropical regions, and Napo has entered two screening relationship associated with this collection. ...

Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations

... form of delivery because they detach from liposomes almost immediately after injection. Celator scientists reported that they were able to generate a library of hydrophobic paclitaxel conjugates incorporated into nanoparticles. In preclinical testing, these nanoparticles were shown to circulate in the ...

OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody

... targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastases. The company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as breast, colon, prostate, and lung cancers. OncoMed is a leader ...

Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea

... for the treatment of insulin resistant diseases of Type II diabetes and metabolic syndrome (Syndrome X; pre-diabetic syndrome). Napo also has a plant library of approximately 2,300 medicinal plants from tropical regions, and Napo has entered two screening relationship associated with this collection. ...

U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older

... 10, 2008. 3 Ravelli A. Juvenile Idiopathic Arthritis. The Lancet. 2007:369:767-778. 4 Medline Plus. Juvenile Rheumatoid Arthritis. US National library of Medicine, National Institute of Health. Available at http://www.nlm.nih.gov/medlineplus/juvenilerheumatoidarthritis.html . Accessed March 10, ...

Gene Hunters Fine-Tune Marker for Common Obesity Gene

... from Children's Hospital and the University of Pennsylvania School of Medicine, reported its findings in the March 12 issue of the journal Public library of Science ONE. The 2007 British group had originally found the FTO gene variant among obese Caucasians. Using samples from Caucasian and African ...

Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine

... company focused on the development and commercialization of new drugs to treat infectious diseases. Immtech has a well defined, expanding library of compounds targeting Hepatitis C, drug- resistant Gram-positive bacteria, fungal infections and other serious diseases. It is expanding its ...

Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea

... for the treatment of insulin resistant diseases of Type II diabetes and metabolic syndrome (Syndrome X; pre-diabetic syndrome). Napo also has a plant library of approximately 2,300 medicinal plants from tropical regions, and Napo has entered two screening relationships associated with this collection. ...

Immtech Announces Posting of Annual Shareholders Meeting Presentation

... that include new treatments for Pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (African sleeping sickness), and a well defined, expanding library of compounds targeting Hepatitis C, fungal infections, and bacterial infections. Immtech holds exclusive worldwide licenses to certain patents, ...

Immtech Reports Fiscal Second Quarter 2008 Results

... new oral treatments for pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (African sleeping sickness or HAT), and a well-defined, expanding library of compounds targeting drug-resistant Gram-positive bacteria, fungal infections, Hepatitis C and other serious diseases. Immtech holds the exclusive ...

Immtech to Present at The Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

... new oral treatments for pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African sleeping sickness), and a well-defined, expanding library of compounds targeting drug-resistant Gram-positive bacteria, fungal infections, Hepatitis C and other serious diseases. Immtech holds the exclusive ...

Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials

... new oral treatments for Pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African sleeping sickness), and a well defined, expanding library of compounds targeting drug-resistant Gram-positive bacteria, fungal infections, Hepatitis C and other serious diseases. Immtech holds the exclusive ...